Emerging Graphene Technology Company
Hydrothermal Graphite Deposit Ammenable for Commercial Graphene Applications
Message: From a link on SI from the minister of health
It looks like our federal government is piling money into companies who have promising products to fight Covid. Edesa a Biotech has received millions for the following anti inflammatory product.
TLR4 and CXCL10 Inhibitors
Our novel monoclonal antibodies suppress certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including the inflammation associated with infectious diseases like COVID-19
Acute Respiratory Distress Syndrome
An Exaggerated Immune Response Leads to Hypoxia & Death
Moderate to severe viral pneumonia triggers exaggerated immune response
- Cell damage, “cytokine storm” and widespread inflammation
- Oxygen cannot permeate air sacks leading to death
Cytokine release and inflammatory response due to viral infection is mediated via TLR4.
Compelling Evidence of Activity
EB05 lowered cytokines after in vivo endotoxin challenge
Inhibits “Cytokine Storm”
A single low dose of EB05 provided a measurable protective response to endotoxin (LPS) challenge for 22+ days
In previous Phase 1 and Phase 2 clinical studies, EB05 and EB06 have demonstrated the ability to resolve fever and stabilize heart and breathing rates in subjects administered immune challenges.
Favorable Safety Profile
Our anti-TLR4 and anti-CXCL10 antibody therapies been administered to >120 subjects without any safety signals.
EB05 lowered fever and stabilized vital signs after in vivo endotoxin (LPS) challenge
The physiological signs observed are consistent with the biological profile measured
Loading...
Loading...
New Message
Please
login
to post a reply